中国医学创新Issue(14)：16-18,3.DOI:10.3969/j.issn.1674-4985.2014.14.006
口服布洛芬治疗动脉导管未闭早产儿的疗效及安全性评价
Evaluation of Efficacy and Safety of Oral Ibuprofen in the Treatment of Preterm Infant with Patent Ductus Arteriosus
熊寒梅 1李湘云 1潘冬妮 1周兴梅1
作者信息
- 1. 云南省昭通市第一人民医院 云南 昭通 657000
- 折叠
摘要
Abstract
Objective:To study efficacy and safety of oral ibuprofen(Motrin suspension)in the treatment of preterm infant with patent ductus arteriosus(PDA). Method:A total of 106 preterm infants with PDA were included 3 to 18 days after birth. The patients were orally administered ibuprofen,and the doses were 10-5-5 mg/kg every 24 hours. Monitoring PDA closure rate,circulatory function,renal function,blood coagulation and the incidence of intracranial hemorrhage were taken before and after the treatment. Result:(1)99 patients(99/106,93.4%)got the closure of PDA.(2)The efficacy was related to the GA. The higher closure rate was in the newborns with GA≥34 weeks(54/56, 96.4%)than ones with GA<34 weeks(45/50,90%),P<0.05. There were no significantly differences in the closure rate between the BW≥2000 g group(49/52,94.2%)and BW <2000 g group(50/54,92.6%),P>0.05.(3)Side effects manifested as a transient oliguria(46.2%),creatinine and urea levels were normal. No thrombocytopenia. Feeding intolerance in preterm children was 29.2%,to a lesser extent,necrotizing enterocolitis does not appear. Aggravation of intracranial hemorrhage was not found. Conclusion:The efficacy and safety of administration of oral ibuprofen for treating PDA in preterm infants are acceptable. However,pharmacokinetics and clinical controlled trials are needed in the future in preterm infants to prove the therapeutic effect and make the efficient regimen.关键词
早产儿/动脉导管未闭/布洛芬Key words
Infant/Premature patent ductus arteriosus/Ibuprofen引用本文复制引用
熊寒梅,李湘云,潘冬妮,周兴梅..口服布洛芬治疗动脉导管未闭早产儿的疗效及安全性评价[J].中国医学创新,2014,(14):16-18,3.
